Become A Featured Company

Medical Cannabis Company Cantourage to list on the Frankfurt Stock Exchange on 11 November 2022

Ryan Allway

November 11th, 2022

News, Top News

  • Following its successful private placement, Cantourage plans to list in the Scale segment on the Frankfurt Stock Exchange
  • First trading day is scheduled for 11 November 2022
  • Company has achieved high double-digit valuation as part of the placement

 

Cantourage Group SE (“Cantourage”), a European medical cannabis leader, announced today that it is seeking a listing on the Scale segment of the Frankfurt Stock Exchange on 11 November 2022. Following the listing, approximately 15% of the company’s shares, a total of nearly two million bearer shares, will be made available in free float on the open market of the Frankfurt Stock Exchange. Following the previously completed private placement, Cantourage will now be valued in the high double-digit million-euro range.

 

Philip Schetter, CEO of Cantourage, says: “Having already achieved revenues of over EUR 5 million in 2021, we are aiming to triple this amount in 2022, especially through Cantourage’s organic growth – and we are continuing to act in a strong growth market. We are happy about the successful private placement and the upcoming listing of our company. It is time to democratise the market for medicinal cannabis in Germany and offer investors the opportunity to participate early on.”

 

According to the German Ministry of Health, in 2021 Germany had the most patient demand for medical cannabis in Europe. More than 20 tons of cannabis for medical purposes have already been imported to Germany this year [1]. Future national demand can only be met through further imports.

 

With the capital raised from the private placement, Cantourage plans to systematically expand its production capacities, enter new markets and prepare for the upcoming legalisation of recreational cannabis in various European countries. The capital market listing provides Cantourage with new avenues for both organic and inorganic growth within the dynamic medical cannabis market.

 

Founded in 2019 by Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann, Cantourage distributes medicinal cannabis flowers, Dronabinol, cannabis extracts and pharmaceutical CBD across Europe and the UK. Cantourage’s platform also enables the import of cannabis into Germany from across the world, for it to then be locally processed into pharmaceutical products and to be distributed to doctors and pharmaceutical wholesalers throughout Europe.

 

Currently, Cantourage maintains 38 partnerships with suppliers from 17 countries across 5 continents, thereby offering a broad and diversified range of products. In the Dronabinol segment, Cantourage has a market share of over 20% in Germany, driven in part by product innovations such as the launch of the first Dronabinol solution [2]. Since the beginning of Q2/2022, Cantourage has also been operating its own cannabis clinic in the UK. The company currently employs over 35 employees in Germany and the UK.

 

The European market for medical cannabis targeted by Cantourage is estimated to grow to €3 billion by 2025 [3], while the size of potential markets in which cannabis could be sold for recreational use is significantly larger. In Germany alone, this market is estimated to be almost 20 times larger than the medical cannabis market [4].

 

Hauck Aufhäuser Investment Banking advised the company as its exclusive financial advisor and listing agent.

 

About Cantourage
Cantourage is a leading European medical cannabis company. The Berlin-based company was founded in 2019 by industry pioneers Norman Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffman. Cantourage enables producers from all over the world to become part of the rapidly growing European medical cannabis market in a faster and more cost-effective way, while guaranteeing and developing the highest European quality standards. The company offers products in all relevant market segments: dried flowers, extracts, Dronabinol and pharma-grade Cannabidiol.

 

Contact for media enquiries:
Roland Leithäuser
Kekst CNC
M +49 162 2074 592
T +49 69 506 037 571
roland.leithaeuser@kekstcnc.com

 

This announcement does not constitute a public offer or an advertisement for a public offer within the meaning of Regulation (EU) 2017/1129 (Prospectus Regulation).

 

This announcement is not an offer of securities for sale in the United States of America. Securities may not be sold or offered in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”). Any public offering of securities to be made in the United States would be made by means of a prospectus that could be obtained from the Company. This prospectus would contain detailed information about the Company and its management, as well as the Company’s financial information. There will be no public offering of the securities referred to in this announcement in the United States of America.
In the United Kingdom, this information may only be communicated to and is only directed at (i) professional investors within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth companies falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to herein as “Relevant Persons”). The Securities are only available to Relevant Persons and any invitation, offer or agreement to subscribe for, purchase or otherwise acquire such Securities will only be engaged in with Relevant Persons. Any person who is not a Relevant Person should not act or rely on this announcement or any of its contents.

 

Subject to certain exceptions, the securities referred to in this announcement may not be sold or offered in Australia, Canada or Japan, or to or for the account or benefit of any national, resident or citizen of Australia, Canada or Japan.

 

 

[1] Source: Prohibition Partners, The European Cannabis Report, 7th Edition, https://www.bfarm.de/DE/Bundesopiumstelle/News/Cannabis/medizinalcannabis-importmengen.html;jsessionid=E83ACD8FFC3AD9C156FD8550139FEFDC.intranet262

[2] Evaluation of Insight Health data from June to August 2022

[3] Prohibition Partners, The European Cannabis Report, 6th Edition, Cantourage Analysis

[4] Düsseldorf Institute for Competition Economics (DICE) 2021, Fiskalische Auswirkungen einer Cannabislegalisierung in Deutschland: Ein Update, https://www.dice.hhu.de/fileadmin/redaktion/Fakultaeten/Wirtschaftswissenschaftliche_Fakultaet/DICE/Bilder/Nachrichten_und_Meldungen/Fiskalische_Effekte_Cannabislegalisierung_final.pdf

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading